Article
When to use which molecular prognostic scoring system in the management of patients with MDS?
Best practice & research. Clinical haematology - 1 Dec 2023
Kewan Tariq, Bewersdorf Jan Philipp, Gurnari Carmelo, Xie Zhuoer, Stahl Maximilian, Zeidan Amer M
Abstract excerpt
Myelodysplastic syndromes/neoplasms (MDS) are a heterogeneous group of hematopoietic cancers characterized by recurrent molecular alterations driving the disease pathogenesis with a variable propensity for progression to acute myeloid leukemia (AML). Clinical decision making for MDS relies on appropriate risk stratification at diagnosis, with higher-risk patients requiring more intensive therapy. The conventional...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.